{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088823","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.918544+00:00","generated_at":"2026-06-12T02:58:26.587982+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Journey Medical Q2 net loss $8.4M, revenue $17.2M; DFD-29 Phase 3 positive, NDA submission H2 2023","bullets":["Q2 2023 net revenues $17.2M, down 6% YoY but up 41% QoQ; core product revenue grew 19% YoY to $15.6M (92% of total).","GAAP net loss $8.4M ($0.46/sh) vs $7.5M loss ($0.43/sh) in Q2 2022; adjusted EBITDA improved to -$0.6M from -$2.6M.","DFD-29 Phase 3 trials met co-primary and all secondary endpoints, superior to placebo and Oracea; NDA submission planned H2 2023.","Non-cash impairment of Ximino intangible asset of $3.1M; SG&A down 20% to $12.1M from cost reduction initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088823","json":"https://secwatch.observer/filing/0001104659-23-088823.json","markdown":"https://secwatch.observer/filing/0001104659-23-088823.md","text":"https://secwatch.observer/filing/0001104659-23-088823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/0001104659-23-088823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/tm2323104d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:58:26.587982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3773230f2ea08977d491065f3af82ce39cdf7f04","claim":"Journey Medical Corp reported the second quarter ended June 30, 2023 results: revenue $17.2 million, net income GAAP net loss was $8.4 million, or $0.46 per share basic and diluted, EPS $0.46 per share basic and diluted.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two Phase 3 clinical trials evaluating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/0001104659-23-088823-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$17.2 million"},{"label":"Net income","value":"GAAP net loss was $8.4 million, or $0.46 per share basic and diluted"},{"label":"EPS","value":"$0.46 per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}